SCHEDULE: ADAR1 Capital Management Discloses 9.9% Stake in Grace Therapeutics

ADAR1 Capital Management, along with affiliates, has reported beneficial ownership of 9.9% of Grace Therapeutics, Inc. common stock, primarily through warrants.

Summary

• ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger have filed a Schedule 13G, indicating their beneficial ownership of Grace Therapeutics, Inc. common stock.
• The reporting persons collectively hold 1,806,216 shares, representing 9.9% of the outstanding common stock as of June 30, 2026.
• This ownership is primarily derived from prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.
• ADAR1 Capital Management acts as the investment manager for ADAR1 Partners, LP and sub-advisor for Spearhead Insurance Solutions IDF, LLC.
• ADAR1 Capital Management GP, LLC is the general partner of ADAR1 Partners, LP.
• Daniel Schneeberger manages ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, and is a citizen of Switzerland.
• The filing is based on 16,274,026 shares of common stock outstanding as of June 30, 2026, as reported in Grace Therapeutics' Form 10Q filed on August 13, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant but not controlling stake in Grace Therapeutics, Inc. by ADAR1 Capital Management and its affiliates. The filing indicates substantial beneficial ownership through warrants, which could imply a positive outlook on the company's future prospects, but it does not contain new operational or financial performance data.

Positives

• Significant beneficial ownership of 9.9% of Grace Therapeutics, Inc. common stock by ADAR1 Capital Management and its affiliates.
• The ownership is based on warrants, suggesting a potential long-term interest and belief in the company's future value.
• The filing is current as of June 30, 2026, reflecting recent holdings.

Negatives

• The filing does not provide any new operational or financial performance data for Grace Therapeutics, Inc.
• A portion of the warrants (69,331 shares) are excluded from the reported beneficial ownership due to 9.99% ownership limitations upon exercise.

Risks

• The exercise of warrants is subject to 9.99% beneficial ownership limitations, which could restrict the full conversion of all held warrants.
• Potential for future changes in beneficial ownership as warrants are exercised or expire.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Grace Therapeutics, Inc. However, the acquisition of beneficial ownership through warrants by ADAR1 Capital Management may imply a positive outlook on the company's future prospects by the reporting persons.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment stakes. The significant ownership by ADAR1 Capital Management, particularly through warrants, suggests a strategic investment in Grace Therapeutics, Inc., potentially anticipating future growth or value realization. This type of filing is common in the biotechnology and pharmaceutical sectors where companies often rely on specialized investment firms for funding and strategic partnerships.

Stakeholder Impact

• Shareholders: The increased stake by a significant investment firm could be viewed positively, potentially indicating confidence in the company's future, but also raises questions about future strategic moves.
• Creditors: No direct impact is indicated by this filing.
• Employees: No direct impact is indicated by this filing.
• Customers/Suppliers: No direct impact is indicated by this filing.

Next Steps

• ADAR1 Capital Management and its affiliates will continue to hold and potentially exercise their warrants.
• Grace Therapeutics, Inc. will continue its operations and financial reporting as usual.

Key Dates

Keywords

Grace Therapeutics, ADAR1 Capital Management, Schedule 13G, Beneficial Ownership, Warrants, Shareholder, Investment Management